• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 22nd May 2020

The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?

The COVID-19 pandemic has highlighted the necessity of finding health solutions in an unprecedentedly short length of time. However, the first treatments, tests and vaccines will only offer partial solutions. Competing follow-on technologies will offer better or complementary health benefits.…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The COVID-19 pandemic has highlighted the necessity of finding health solutions in an unprecedentedly short length of time. However, the first treatments, tests and vaccines will only offer partial solutions. Competing follow-on technologies will offer better or complementary health benefits. It is essential that health systems do not put all of their eggs in one basket.

The colossal health and economic shock caused by COVID-19 has highlighted the vital role that the public and private sectors play in finding health solutions and producing them in massive quantities in an unprecedentedly short length of time. However, the first treatments, tests and (hopefully) vaccines developed and used will only offer partial solutions. Competing follow-on technologies will offer better or complementary health benefits. It is essential that health systems do not put all of their eggs in one basket.

The rapid spread of the novel coronavirus (SARS-CoV-2) – known as Coronavirus Disease 2019 (COVID-19) – from Wuhan, China in December 2019 to 188 countries around the world with (at time of publication) 312k deaths and 4.6 million infected) has put governments under pressure to make difficult political choices.

In the EU, one of the most affected areas, most countries have implemented population lockdowns of different degrees including school closures, citizen confinements, non-essential business closures and banning public events. 

The aim is to ‘flatten the curve’ of new infections, providing some relief to health care systems to reduce potential deaths. But lockdowns have dramatic negative economic and social consequences – a GDP decrease of 20%-30% for the G7 – with associated mortality and morbidity.  When countries (i.e. Spain, Italy, UK, France) see lockdowns have ‘flattened the curve’, they rush to exit them judging that the marginal (economic and health) benefit of exiting exceeds the marginal cost of maintaining lockdown. The development of innovative health technologies including diagnostic tests, new or repurposed effective therapies, and vaccines, are crucial to further changing the benefit-cost balance. Their potential to generate health and economic net value is huge. Not surprisingly, a global R&D effort to discover and/or scale up production of potentially effective solutions has been triggered. R&D is being funded by the private sector, and by governments (e.g., UK, Spain, US, Canada) and foundations with  a total of 118  vaccine candidates under development (8 in clinical evaluation), and a long list of drug candidates with around 800 clinical trials investigating  COVID-19 therapies.  Finally, testing diagnostics, for both active infection and for antibodies, are in a development race to improve  specificity and sensitivity.

In the fight against COVID-19, Governments are learning by doing in public health interventions, using the experiences of their neighbours as positive or negative examples. Learning by doing will also characterise the development of innovative health technologies to fight the COVID-19, as more is known about the disease, better innovative solutions will be developed. However, in the current context the fast adoption and wide global access to the early but imperfect technologies might help to save huge health loss and economic cost. In the case of COVID-19 antibody tests, for instance, massive testing with an imperfect test will improve the effectiveness of exiting lockdown saving huge socio-economic costs. The first (likely imperfect) vaccines or new treatments making it to the market promise even higher expected benefits. Thus, two crucial policy questions arise: how to organise and regulate global markets to incentivise the timely and successful development and supply of innovative solutions to fight COVID-19?; and, how to keep competition going to incentivise the development and adoption of new improved versions of such solutions?

There is no guarantee that we have a pathway to developing the most effective diagnostic tests, treatments, and vaccines. A globally optimal outcome requires three things:

  1. Countries’ cooperating for the common good. As Bill Gates noted “some markets simply don’t function properly in a pandemic, and the market for life-saving supplies is an obvious example. The private sector has an important role to play, but if our strategy for fighting COVID-19 devolves into a bidding war among countries, this disease will kill many more people than it has to”.
  2. Mechanisms which provide incentives for continued private sector research and which reward investment. Proposals have been made for compulsory licencing of COVID-19 treatments and vaccines. However, this will reduce private sector willingness to invest at risk, increasing reliance on government and donor “push” funding of research, development, and manufacturing.
  3. Mechanisms which reward follow-on products rather than a ‘winner takes all’ approach. Multi-country patent buy-outs at a value-based price or an international COVID-19 Impact Fund have been proposed for new tests, products or vaccines. These could be efficient solutions for the first tests, vaccines or treatments making it to the market but developers of other tests, treatments, and vaccines of equivalent or better quality could lose out. Competition for development of better tests, treatments and vaccines would then be discouraged because rewards and purchase contracts were directed at the first to market. Investment in potentially better technologies offering more health gain and economic benefit would be abandoned and never reach the market.

One route forward is a benefit-based AMC, which has been proposed for a COVID-19 vaccine by authors from the Center for Global development (CGD), Program for Appropriate Technology in Health (PATH), and OHE. This is based on the Market-Driven Value-based Advance Commitment (MVAC) and designed to aggregate advance commitments by individual countries into a minimum guaranteed market for companies that are able to meet the agreed Target Product Profile (TPP). Value-based prices will be set in advance using Health Technology Assessment tools, varying by product, depending on how well the technology meets the TPP, and by country depending on ability to pay. Differential pricing would ensure that low income countries had access at cost, supported by donors, for example through The Vaccines Alliance (Gavi). Rules could be pre-agreed for priority allocations between countries whilst manufacturing volumes were being scaled up. 

A key part of the proposal is to incentivise the development of improved vaccines that could enter the market in future periods and to provide for competition between vaccines by (i) agreeing guaranteed value-based minimum prices in each country for products that meet the TPP threshold, and, (ii) allowing competition with governments deciding how to efficiently spend their advance commitment as between different vaccines.

The benefit-based AMC framework could be used for new treatments and for new diagnostic tests. It is intended to address the challenge laid down by Bill Gates – that in pandemic circumstances normal market mechanisms do not work. We risk a free-for-all bidding competition mirrored by calls for the abandonment of the intellectual property protection that is needed for long term private sector investment by those who fear they will lose out from such a competition.

Perhaps most importantly of all, we need market mechanisms that recognise that getting an optimal mix of different types of tests, treatments and vaccines will take time and requires rewarding the engagement of private sector research, development and manufacturing, as well using the resources and skills of government and of academic researchers. We will “learn by doing” using knowledge generated by discovery, by clinical development, and by clinical practice to get better use of new technologies as they appear and to develop better technologies that deliver more health and economic gain.

Related Research

Chalkidou, K., Towse, A., Silverman, R., Garau, M., & Ramakrishnan, G. (2020). Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. BMJ Global Health, 5(4), e002061. Available at: https://gh.bmj.com/content/bmjgh/5/4/e002061.full.pdf

  • COVID-19 Research
  • Economics of Innovation
  • Innovation

Related Insights

Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!